KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Change in Inventory: 2009-2024

Historic Change in Inventory for Halozyme Therapeutics (HALO) over the last 16 years, with Dec 2024 value amounting to $67.4 million.

  • Halozyme Therapeutics' Change in Inventory rose 155.61% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.0 million, marking a year-over-year decrease of 58.83%. This contributed to the annual value of $67.4 million for FY2024, which is 150.64% up from last year.
  • Halozyme Therapeutics' Change in Inventory amounted to $67.4 million in FY2024, which was up 150.64% from $26.9 million recorded in FY2023.
  • In the past 5 years, Halozyme Therapeutics' Change in Inventory registered a high of $67.4 million during FY2024, and its lowest value of -$7.4 million during FY2021.
  • Over the past 3 years, Halozyme Therapeutics' median Change in Inventory value was $26.9 million (recorded in 2023), while the average stood at $37.2 million.
  • In the last 5 years, Halozyme Therapeutics' Change in Inventory surged by 366.11% in 2020 and then slumped by 123.48% in 2021.
  • Over the past 5 years, Halozyme Therapeutics' Change in Inventory (Yearly) stood at $31.4 million in 2020, then plummeted by 123.48% to -$7.4 million in 2021, then soared by 337.16% to $17.5 million in 2022, then soared by 53.79% to $26.9 million in 2023, then spiked by 150.64% to $67.4 million in 2024.